BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 30563882)

  • 21. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
    Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
    Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The expression of MDM2, MDM4, p53 and p21 in myeloid neoplasms and the effect of MDM2/MDM4 dual inhibitor.
    Eskandari M; Shi Y; Liu J; Albanese J; Goel S; Verma A; Wang Y
    Leuk Lymphoma; 2021 Jan; 62(1):167-175. PubMed ID: 32924682
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The orally bioavailable MDM2 antagonist RG7112 and pegylated interferon α 2a target JAK2V617F-positive progenitor and stem cells.
    Lu M; Xia L; Li Y; Wang X; Hoffman R
    Blood; 2014 Jul; 124(5):771-9. PubMed ID: 24869939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Flow cytometry immunophenotypic analysis of Philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features.
    Ouyang J; Zheng W; Shen Q; Goswami M; Jorgensen JL; Medeiros LJ; Wang SA
    Cytometry B Clin Cytom; 2015; 88(4):236-43. PubMed ID: 25557358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors.
    Cerquozzi S; Tefferi A
    Blood Cancer J; 2015 Nov; 5(11):e366. PubMed ID: 26565403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Research progress on molecular pathogenesis of myeloproliferative neoplasms].
    Liu L; Xiao ZJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):239-43. PubMed ID: 21362261
    [TBL] [Abstract][Full Text] [Related]  

  • 27. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 28. JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms.
    Eickhardt-Dalbøge CS; Nielsen HV; Fuursted K; Stensvold CR; Andersen LOB; Lilje B; Larsen MK; Kjær L; Christensen SF; Knudsen TA; Skov V; Sørensen AL; Ellervik C; Olsen LR; Christensen JJE; Nielsen XC; Hasselbalch HC; Ingham AC
    Eur J Haematol; 2024 May; 112(5):776-787. PubMed ID: 38226781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accelerated Phase of Myeloproliferative Neoplasms.
    Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
    Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GATA1 downregulation in prefibrotic and fibrotic stages of primary myelofibrosis and in the myelofibrotic progression of other myeloproliferative neoplasms.
    Sangiorgio VFI; Nam A; Chen Z; Orazi A; Tam W
    Leuk Res; 2021 Jan; 100():106495. PubMed ID: 33360878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.
    Rotunno G; Pacilli A; Artusi V; Rumi E; Maffioli M; Delaini F; Brogi G; Fanelli T; Pancrazzi A; Pietra D; Bernardis I; Belotti C; Pieri L; Sant'Antonio E; Salmoiraghi S; Cilloni D; Rambaldi A; Passamonti F; Barbui T; Manfredini R; Cazzola M; Tagliafico E; Vannucchi AM; Guglielmelli P
    Am J Hematol; 2016 Jul; 91(7):681-6. PubMed ID: 27037840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone marrow megakaryocytic activation predicts fibrotic evolution of Philadelphia-negative myeloproliferative neoplasms.
    Schino M; Fiorentino V; Rossi E; Betti S; Di Cecca M; Ranucci V; Chiusolo P; Martini M; De Stefano V; Larocca LM
    Haematologica; 2021 Dec; 106(12):3162-3169. PubMed ID: 33543865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dkk3 levels in patients with myeloproliferative neoplasms.
    Medinger M; Muesser P; Girsberger S; Skoda R; Tzankov A; Buser A; Passweg J; Tsakiris DΑ
    Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Myeloproliferative diseases caused by JAK2 mutation].
    Nagata K; Shimoda K
    Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chromosome 1 abnormalities in myeloid malignancies: a literature survey and karyotype-phenotype associations.
    Caramazza D; Hussein K; Siragusa S; Pardanani A; Knudson RA; Ketterling RP; Tefferi A
    Eur J Haematol; 2010 Mar; 84(3):191-200. PubMed ID: 20002154
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BCR-ABL negative myeloproliferative neoplasia: a review of involved molecular mechanisms.
    Koopmans SM; Schouten HC; van Marion AM
    Histol Histopathol; 2015 Feb; 30(2):151-61. PubMed ID: 25196073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm.
    Wang JC; Kundra A; Andrei M; Baptiste S; Chen C; Wong C; Sindhu H
    Leuk Res; 2016 Apr; 43():39-43. PubMed ID: 26943702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Analysis of CHIP-Related Mutation and Risk of Cardio-Cerebrovasculars Events in Patients with Myeloproliferative Neoplasms].
    Han X; Bai BB; Feng CC; Zhao S; Chen Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):190-196. PubMed ID: 38387920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Towards a Personalized Definition of Prognosis in Philadelphia-Negative Myeloproliferative Neoplasms.
    Mora B; Passamonti F
    Curr Hematol Malig Rep; 2022 Oct; 17(5):127-139. PubMed ID: 36048275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
    Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
    Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.